Patents Represented by Attorney Richard S. Parr

Find this attorney in the Justia Lawyer Directory

  • Methods for administering integrin receptor antagonists
    Patent number: 5900414
    Abstract: The compositions and methods of the invention provide a convenient means for systemically administering an integrin receptor antagonist or a pharmaceutically effective amount thereof to a patient by introducing the antagonist, in an ophthalmic formulation, to the patient's eye.
    Type: Grant
    Filed: August 26, 1997
    Date of Patent: May 4, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Michael F. Sugrue, George D. Hartman, Robert J. Gould
  • Fibrinogen receptor antagonist
    Patent number: 5889023
    Abstract: A fibrinogen receptor antagonist which is 3(R)-?2-(Piperidin-4-yl)ethyl!-2-piperidon-1-ylacetyl-3(S)-(3-pyridyl)-.be ta.-alanine.
    Type: Grant
    Filed: May 5, 1997
    Date of Patent: March 30, 1999
    Assignee: Merck & Co., Inc.
    Inventors: John H. Hutchinson, George D. Hartman, Wasyl Halczenko
  • Sulfonamide fibrinogen receptor antagonists
    Patent number: 5880136
    Abstract: A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: March 9, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Melissa S. Egbertson, Wasyl Halczenko, George D. Hartman, William L. Laswell
  • Thrombin inhibitors
    Patent number: 5872138
    Abstract: A compound which inhibits human thrombin and which has the general structure ##STR1##
    Type: Grant
    Filed: September 10, 1997
    Date of Patent: February 16, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Adel M. Naylor-Olsen, Gerald S. Ponticello, Joseph P. Vacca, Randall W. Hungate, Craig Coburn, Brian T. Phillips, S. D. Lewis, Mark E. Fraley
  • Pyrido?3,4-B!pyrazines for use as thrombin inhibitors
    Patent number: 5869487
    Abstract: A compound which inhibits human thrombin and where has the structure ##STR1##
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: February 9, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Craig Coburn, Christine Kolatac, Diane M. Rush, Joseph P. Vacca
  • Pyrazinone thrombin inhibitors
    Patent number: 5866573
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: ##STR1## for example: ##STR2##
    Type: Grant
    Filed: April 21, 1997
    Date of Patent: February 2, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Philip E.. Sanderson, Terry A.. Lyle, Bruce D. Dorsey, Richard J. Varsolona
  • Fibrinogen receptor antagonists
    Patent number: 5854245
    Abstract: Fibrinogen receptor antagonists having the structureX--Y--Z--A--Band pharmaceutically acceptable salts, wherein X is a 5, 6 or 7 membered aromatic or nonaromatic ring, and Y is a 5 or 6 membered aromatic ring, e.g.
    Type: Grant
    Filed: June 26, 1997
    Date of Patent: December 29, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Melissa S. Egbertson, George D. Hartman, Steven D. Young, Nathan C. Ihle
  • Method for preventing heartburn
    Patent number: 5854267
    Abstract: A method for preventing heartburn episodes in a patient susceptible to suffering heartburn episodes following ingestion of heartburn-inducing food or beverage, comprising administering to the patient, 30 minutes prior to consumption by the patient of the food or beverage, a composition comprising an amount of famotidine of 10 mg.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 29, 1998
    Assignees: Merck & Co., Inc., Mc Neil-PPC, Inc.
    Inventors: Roger Berlin, Thomas N. Gates, Thomas Simon
  • Fibrinogen receptor antagonists
    Patent number: 5852045
    Abstract: Fibrinogen receptor antagonists having the structure, for example, of ##STR1## for example ##STR2##
    Type: Grant
    Filed: October 15, 1996
    Date of Patent: December 22, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Ben C. Askew, George D. Hartman, Mark E. Duggan, Steven D. Young, John H. Hutchinson, John S. Wai, Melissa S. Egbertson, Laura M. Vassallo, Laura A. Libby, Amy E. Krause, Wasyl Halczenko, Nathan C. Ihle
  • Fibrinogen receptor antagonists
    Patent number: 5821241
    Abstract: Compounds of the invention have the formula ##STR1## The compounds have fibrinogen receptor antagonist activity.
    Type: Grant
    Filed: August 1, 1995
    Date of Patent: October 13, 1998
    Assignee: Merck & Co., Inc.
    Inventors: David Alan Claremon, John J. Baldwin, Nigel Liverton, Ben Askew
  • Human A3 adenosine receptors
    Patent number: 5817760
    Abstract: The invention concerns recombinant human adenosine receptors A1, A2a, A2b and A3 which have been prepared by cDNA cloning and polymerase chain reaction techniques. The invention also concerns expression systems for these receptors and an assay using the expression systems. The recombinant adenosine receptors comprising the invention can be utililized in an assay to identify and evaluate entities that bind to or enhance binding to adenosine receptors.
    Type: Grant
    Filed: March 27, 1996
    Date of Patent: October 6, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Marlene A. Jacobson, Christopher J. Luneau, Robert G. Johnson, Christopher A. Salvatore
  • Sulfonamide fibrinogen receptor antagonists
    Patent number: 5814643
    Abstract: A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.
    Type: Grant
    Filed: May 22, 1997
    Date of Patent: September 29, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Melissa S. Egbertson, Wasyl Halczenko, George D. Hartman, William L. Laswell
  • Thrombin inhibitors
    Patent number: 5798377
    Abstract: A compound which inhibits human thrombin and where has the structure ##STR1## such as ##STR2##
    Type: Grant
    Filed: October 21, 1996
    Date of Patent: August 25, 1998
    Assignee: Merck & Co., Inc.
    Inventors: William C. Lumma, Thomas J. Tucker, Keith M. Witherup, Stephen F. Brady, Willie L. Whitter, Joseph P. Vacca, Craig Coburn, Jules A. Shafer
  • Thrombin inhibitors
    Patent number: 5792761
    Abstract: A compound which inhibits human thrombin and where has the structure ##STR1##
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: August 11, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Adel M. Naylor-Olsen, Randall W. Hungate, Joseph P. Vacca
  • Pyridinone thrombin inhibitors
    Patent number: 5792779
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions and have the following structure: ##STR1## for example: ##STR2##
    Type: Grant
    Filed: February 19, 1997
    Date of Patent: August 11, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Philip E. Sanderson, Terry A. Lyle, Joseph P. Vacca, William C. Lumma, Stephen F. Brady, Thomas J. Tucker
  • Fibrinogen receptor antagonist
    Patent number: 5789421
    Abstract: A fibrinogen receptor antagonist which is 5-?(4-Piperidinyl)methoxy!-2-indolecarbonyl-2(S)-phenylsulfonyl-amino-.bet a.-alanine.
    Type: Grant
    Filed: October 23, 1996
    Date of Patent: August 4, 1998
    Assignee: Merck & Co., Inc.
    Inventors: John H. Hutchinson, Wasyl Halczenko
  • Fibrinogen receptor antagonists
    Patent number: 5786373
    Abstract: Novel fibrinogen receptor antagonists of the formula: X--Y--Z-Aryl-A--B and the pharmaceutically acceptable salts thereof, wherein Aryl is a 5-membered aromatic ring system containing 1 or 2 heteroatoms chosen from N, O or S wherein ring atoms may be unsubstituted or substituted with R.sup.5 and wherein S may be substituted with 0, 1 or 2 oxygen atoms; and X comprises various Nitrogen substituents including aromatic or nonaromatic systems; Y comprises, for example, alkyl or alkylaminocarbonylalkyl groups and Z and A are substituents which when present are independently chosen from alkyl or alkyloxyalkyl or other groups as defined herein; B is (a) or (b). The claimed compounds exhibit fibrinogen receptor antagonist activity, inhibit platelet aggregation and are therefore useful in modulating or preventing thrombus formation.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: July 28, 1998
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, John D. Prugh, Melissa S. Egbertson, Mark E. Duggan, William Hoffman
  • Fibrinogen receptor antagonists
    Patent number: 5780480
    Abstract: Fibrinogen receptor antagonists of the general formula:X-A-Y-Z-B Iand which includes, for example, the compounds of formula ##STR1## are useful for inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus formation or embolus formation, and preventing thrombus or embolus formation.
    Type: Grant
    Filed: February 26, 1997
    Date of Patent: July 14, 1998
    Assignee: Merck & Co., Inc.
    Inventors: John Wai, Thorsten E. Fisher, Mark E. Duggan, George D. Hartman, James J. Perkins
  • Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
    Patent number: 5780481
    Abstract: The invention is a method for inhibiting activation of the human A3 adenosine receptor with adenosine, by treating the receptor a compound of the formula ##STR1## to treat asthma.
    Type: Grant
    Filed: August 8, 1996
    Date of Patent: July 14, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Marlene A. Jacobson, Richard Norton, Prasun K. Chakravarty
  • Process for regioselective substitution of trifluorobenzoate or trifluorobenzonitrile
    Patent number: 5777123
    Abstract: The invention provides a process for regioselective substitution of trifluorobenzoate/trifluorobenzonitrile to afford the difluorobenzoate/difluorobenzonitrile in good yields. The resulting difluorobenzoate/difluorobenzonitrile can again be regioselectively substituted with a second nucleophile to give monofluorobenzoate/monofluorobenzonitrile also in good yields. This process is particularly useful for forming key intermediates in the synthesis of oxytocin antagonist compounds.
    Type: Grant
    Filed: February 27, 1997
    Date of Patent: July 7, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Joseph E. Lynch, Yao-Jun Shi, Kenneth M. Wells